← Human Trials & Peer-Reviewed Studies
Insulin degludec improves long-term glycaemic control similarly to insulin glargine but with fewer hypoglycaemic episodes in patients with advanced type 2 diabetes on basal-bolus insulin therapy
Plain-language guide to PMID 25387855 (2015): randomized controlled trial study of Insulin Glargine.
Key Facts
- PMID
- 25387855
- Journal
- Diabetes, obesity & metabolism
- Year
- 2015
- Study type
- Randomized Controlled Trial
- Authors
- Hollander P et al. (10 authors)
- DOI
- 10.1111/dom.12411
- Registered trial
- NCT00972283
What This Study Did, in Plain Language
What Was Tested
This randomized controlled trial paper looks at Insulin Glargine.
How the Study Was Run
The researchers set it up as a randomized study.
The participants were allocated by chance, so the Insulin Glargine group and the comparison group should start out alike.
The timeline in the abstract includes 78 weeks.
What Was Measured
The subject headings attached to it are Blood Glucose, Diabetes Mellitus, Type 2, Glycated Hemoglobin, Hypoglycemia, Hypoglycemic Agents and Insulin, Long-Acting.
Author keywords: glycaemic control, hypoglycaemia, insulin degludec and type 2 diabetes.
What This Means in Plain Language
The paper is a randomized study of Insulin Glargine over 78 weeks.
The publication is from 2015 (Diabetes, obesity & metabolism), a journal based in England.
More context: the Insulin Glargine compound page, all human trials.
Our Notes on the Compound
Insulin Glargine: A long-acting insulin analog given once daily; brands include Lantus, Toujeo, Basaglar and Semglee.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.